CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial
Abstract Background A substantial proportion of breast cancer patients develop metastatic disease, with over 450,000 deaths globally per year. Bone is the most common first site of metastatic disease accounting for 40% of all first recurrence and 70% of patients with advanced disease develop skeleta...
Main Authors: | Rob Coleman, Janet Brown, Emma Rathbone, Louise Flanagan, Amber Reid, Jessica Kendall, Sacha Howell, Chris Twelves, Carlo Palmieri, Anjana Anand, Iain MacPherson, Sarah Brown |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-01-01
|
Series: | Trials |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13063-019-3643-6 |
Similar Items
-
A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results
by: Brown, J., et al.
Published: (2022) -
Can radium 223 be a conservative non-surgical management of medication-related osteonecrosis of the jaw?
by: Renato Patrizio Costa, et al.
Published: (2019-01-01) -
Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC
by: Viviana Frantellizzi, et al.
Published: (2020-10-01) -
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
by: Axel Heidenreich, et al.
Published: (2019-01-01) -
Combinatorial effect of radium-223 and irreversible electroporation on prostate cancer bone metastasis in mice
by: Raniv D. Rojo, et al.
Published: (2021-01-01)